Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation, Psychiatric, Psychiatric, Tobacco Consumers |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/17/2019 |
| Start Date: | October 2013 |
| End Date: | October 2018 |
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting
treatment of smoking cessation for individuals with panic attacks. The investigators
hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence
greater smoking abstinence rates and decreased panic symptoms after receiving a combined
CBT-based treatment for smokers with panic attacks.
treatment of smoking cessation for individuals with panic attacks. The investigators
hypothesize that individuals receiving DCS (versus those receiving placebo) will evidence
greater smoking abstinence rates and decreased panic symptoms after receiving a combined
CBT-based treatment for smokers with panic attacks.
Inclusion Criteria:
- Male and female patients ages 18-65 capable of providing informed consent
- Willing and able to provide informed consent, attend all study visits and comply with
the protocol
- Daily smoker for at least one year
- Currently smoke an average of at least 8 cigarettes per day
- Report a motivation to quit smoking in the next month of at least 5 on a 10-point
scale
- Evidence of panic attack within the past year and endorsement of smoking as an emotion
regulation strategy (i.e., score at least a 78 on the SAEQ).
Exclusion Criteria:
- Subjects who do not use smoking as an emotion regulation strategy
- Current diagnosis of a psychotic, eating, developmental or bipolar disorder
- Significant suicide risk as determined by structured interview
- Pregnant women, lactating women, and women of childbearing potential who are not using
medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier
devices, condoms and foam, or implanted progesterone rods stabilized for at least 3
months).
- Psychoactive substance abuse or dependence (excluding nicotine dependence) within the
past 6 months
- Current use of isoniazid or ethionamide compounds
- A history of significant medical condition and/or be deemed as currently unhealthy in
the context of a complete physical examination
- Limited mental competency and the inability to give informed, voluntary, written
consent to participate
- Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided
by the researchers during the quit attempt
- Concurrent psychotherapy initiated within three months of baseline, or ongoing
psychotherapy of any duration directed specifically toward treatment of anxiety or
mood disorder other than general supportive therapy initiated at least 3 months prior
to the study
- Use of other tobacco products
- Plans to move outside of the immediate area in the next six months
- Insufficient command of the English language
We found this trial at
1
site
Austin, Texas 78712
Principal Investigator: Jasper A Smits, PhD
Phone: 512-471-5935
Click here to add this to my saved trials
